>Since Mr. Reed has urged us to follow the money trail, and after my talk with the banker last week, I was pleased to see that others are looking at ethical stem cells as an investment. The business journal, Bloomberg, reported on several companies that are involved in ethical stem cell research. Evidently, these companies … Continue reading
Since Mr. Reed has urged us to follow the money trail, and after my talk with the banker last week, I was pleased to see that others are looking at ethical stem cells as an investment. The business journal, Bloomberg, reported on several companies that are involved in ethical stem cell research. Evidently, these companies … Continue reading
>I edited yesterday’s first article on the Amniotic/Placental stem cells reported in Nature Biotechnology. I had mispelled “De Coppi” and had mistakenly reported that Krabbe’s disease was the focus of the experiments with fetal tissue implants in young Daniel Kerner. In fact, Daniel is being treated for Batten’s Disease.
I edited yesterday’s first article on the Amniotic/Placental stem cells reported in Nature Biotechnology. I had mispelled “De Coppi” and had mistakenly reported that Krabbe’s disease was the focus of the experiments with fetal tissue implants in young Daniel Kerner. In fact, Daniel is being treated for Batten’s Disease.
Don C. Reed, a rabid supporter of embryonic stem cell research – and, it seems, only stem cell research – has written an editorial, “Coincidence or Con-Job?” He flatly states that he believes that we are witnessing an act of “weapons of mass deception” in the timing of the release of the newest issue of … Continue reading